Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape
Summary
These costs are passed on to patients in the form of higher drug prices and insurance premiums.Lindus Health is disrupting the $112B CRO industry with its tech-first "anti-CRO" approach, thanks to a combination of in-house technology and vertical integration of services. ""The last 20 years have seen huge breakthroughs in fundamental scientific research, but this isnt impacting the general population because of the artificial bottleneck that clinical trials create," said Michael Young, co-founder of Lindus Health. "In an industry marked by slow growth and fragmentation, their vision for how clinical trials should operate and unwavering commitment to help improve patient outcomes puts them on a completely different playing field than other companies in this space. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records.Clinical trials are the biggest bottleneck to advances in healthcare. Baldertons current portfolio includes: Aircall, Beauty Pie, Contentful, Dream Games, GoCardless, Lendable, Matillion, Merama, Photoroom, Revolut, Tibber, Wayve, Writer and ZOE.